Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis:: the experience of the Spanish Germ-Cell Cancer Group (GG)

被引:91
作者
Germà-Lluch, JR [1 ]
del Muro, XG [1 ]
Maroto, P [1 ]
Paz-Ares, L [1 ]
Arranz, JA [1 ]
Gumà, J [1 ]
Alba, E [1 ]
Sastre, J [1 ]
Aparicio, J [1 ]
Fernández, A [1 ]
Barnadas, A [1 ]
Terrassa, J [1 ]
Sáenz, A [1 ]
Almenar, D [1 ]
López-Brea, M [1 ]
Climent, MA [1 ]
Sánchez, MA [1 ]
de la Vega, RL [1 ]
Berenguer, G [1 ]
Pérez, C [1 ]
机构
[1] Hosp Duran & Reynals, Inst Catala Oncol, Dept Med Oncol, Barcelona 08907, Spain
关键词
germ-cell tumours; testicular cancer;
D O I
10.1016/S0302-2838(02)00439-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To describe the clinical characteristics and treatment results obtained with the application of a homogeneous treatment protocol in 1490 patients with germ-cell tumours (GCT) registered in the 55 hospitals belonging to the Spanish Germ-Cell Cancer Group (GG) during the period between January 1994 and April 2001. Methods: In general, surveillance was the common policy for stage I patients without local poor prognosis factors, whereas they received adjuvant chemotherapy in case those factor were present. Chemotherapy schedules used in advanced cases were cisplatin and etoposide (EP) for seminoma and BEP or BOMP-EPI in non-seminoma, according to whether the patient was in the good or poor prognosis IGCCCG (International Germ-Cell Cancer Collaborative Group) group. Excision of residual masses was mandatory in non-seminomatous germ-cell tumour (NSGCT). Results: Initial local symptomatology was increased testis size in 90% of cases. Sonography was an excellent diagnostic tool to suggest tumour. Non-seminoma (64.2%) was more frequent than seminoma (35.8%). Approximately 10% had the antecedent of cryptorchidism. Non-seminoma patients were 7 years younger than seminoma. Right testis was involved predominantly. Pre-orchidectomy tumour markers were elevated in 21% of seminoma (betaHGC) and 79% in non-seminoma (alphaFP and/or betaHGC). Scrotum violation occurred in only 1.8%. There were significant differences among stage I and the IGCCCG prognosis groups related to a longer interval between the first symptom and orchiectomy. Eighteen percent of non-seminomatous germ-cell tumour belonged to the poor prognosis IGCCCG group. With a median follow-up to 33 months, this series has achieved a 3 year overall survival of 98% for seminoma and 94% for non-seminoma. Only 10% of excised residual masses present after chemotherapy contained malignant cells. Conclusion: Spanish GCT have a similar clinical pattern to that described in the other occidental countries except for a slight increased proportion of non-seminoma upon seminoma. Co-operative groups as GG are unique structures to obtain quick and wide experience on the treatment of testis tumours, contributing to achieve a high cure rate. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:553 / 562
页数:10
相关论文
共 27 条
[1]   E400P in advanced seminoma of good prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification:: The Spanish Germ Cell Cancer Group experience [J].
Arija, JAA ;
del Muro, XG ;
Gumà, J ;
Aparicio, J ;
Salazar, R ;
Saenz, A ;
Carles, J ;
Sánchez, M ;
Germà-Lluch, JR .
ANNALS OF ONCOLOGY, 2001, 12 (04) :487-491
[2]   Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors [J].
Böhlen, D ;
Borner, M ;
Sonntag, RW ;
Fey, MF ;
Studer, UE .
JOURNAL OF UROLOGY, 1999, 161 (04) :1148-1152
[3]   Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy [J].
Bower, M ;
Newlands, ES ;
Holden, L ;
Rustin, GJS ;
Begent, RHJ .
ANNALS OF ONCOLOGY, 1997, 8 (05) :477-483
[4]   Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma [J].
Collette, L ;
Sylvester, RJ ;
Stenning, SP ;
Fossa, SD ;
Mead, GM ;
de Wit, R ;
de Mulder, PHM ;
Neymark, N ;
Lallemand, E ;
Kaye, SB .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (10) :839-846
[5]   Adjuvant treatment of clinical stage I seminoma:: Is a single course of carboplatin sufficient? [J].
Dieckmann, KP ;
Brüggeboes, B ;
Pichlmeier, U ;
Küster, J ;
Müllerleile, U ;
Bartels, H .
UROLOGY, 2000, 55 (01) :102-106
[6]  
Foster RS, 1998, SEMIN ONCOL, V25, P145
[7]   Surveillance for stage I testicular germ cell tumours:: results and cost benefit analysis of management options [J].
Francis, R ;
Bower, M ;
Brunström, G ;
Holden, L ;
Newlands, ES ;
Rustin, GJS ;
Seckl, MJ .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (15) :1925-1932
[8]   Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: A single-institution experience [J].
Gerl, A ;
Clemm, C ;
Schmeller, N ;
Hartenstein, R ;
Lamerz, R ;
Wilmanns, W .
BRITISH JOURNAL OF CANCER, 1996, 74 (08) :1280-1285
[9]  
Germa Lluch J R, 1993, Br J Urol, V71, P473
[10]   BOMP EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors:: The Spanish Germ-Cell Cancer Group experience (GG) [J].
Germà-Lluch, JR ;
del Muro, XG ;
Tabernero, JM ;
Sánchez, M ;
Aparicio, J ;
Alba, E ;
Barnadas, A .
ANNALS OF ONCOLOGY, 1999, 10 (03) :289-293